

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

1. Name and Address of Reporting Person* <u>GTCR INVESTMENT XI LLC</u>  (Last) (First) (Middle) C/O GTCR LLC 300 N. LASALLE SUITE 5600  (Street) CHICAGO IL 60654  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>MARAVAI LIFE SCIENCES HOLDINGS, INC. [ MRVI ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 11/24/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Common Stock	11/24/2020		D <sup>(1)</sup>		1,319,148 <sup>(1)</sup>	D	\$25.515	27,646,515 <sup>(2)(3)</sup>	I	See footnotes <sup>(2)(3)</sup>
Class B Common Stock	11/24/2020		J <sup>(4)</sup>		7,680,852 <sup>(4)</sup>	D	<sup>(4)</sup>	160,974,129 <sup>(5)</sup>	I	See footnote <sup>(5)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Common Units	<sup>(7)</sup>	11/24/2020		D <sup>(1)</sup>			55,823,011 <sup>(1)</sup>	<sup>(6)</sup>	<sup>(6)</sup>	Class A Common Stock	160,974,129	\$25.515	160,974,129	I	See footnote <sup>(7)</sup>

1. Name and Address of Reporting Person\*  
GTCR INVESTMENT XI LLC  
 (Last) (First) (Middle)  
 C/O GTCR LLC  
 300 N. LASALLE SUITE 5600  
 (Street)  
 CHICAGO IL 60654  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
MARAVAI LIFE SCIENCES HOLDINGS, LLC  
 (Last) (First) (Middle)  
 C/O MARAVAI LIFE SCIENCES HOLDINGS, INC.  
 10770 WATERIDGE CIRCLE SUITE 200  
 (Street)  
 SAN DIEGO CA 92121  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
MARAVAI LIFE SCIENCES HOLDINGS 2, LLC  
 (Last) (First) (Middle)  
 C/O MARAVAI LIFE SCIENCES HOLDINGS, INC.  
 10770 WATERIDGE CIRCLE SUITE 200  
 (Street)  
 SAN DIEGO CA 92121  
 (City) (State) (Zip)

1. Name and Address of Reporting Person*		
<a href="#">GTCR FUND XI/B LP</a>		
(Last)	(First)	(Middle)
C/O GTCR LLC		
300 N. LASALLE SUITE 5600		
(Street)		
CHICAGO	IL	60654
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
<a href="#">GTCR FUND XI/C LP</a>		
(Last)	(First)	(Middle)
C/O GTCR LLC		
300 N. LASALLE SUITE 5600		
(Street)		
CHICAGO	IL	60654
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
<a href="#">GTCR CO-INVEST XI LP</a>		
(Last)	(First)	(Middle)
C/O GTCR LLC		
300 N. LASALLE SUITE 5600		
(Street)		
CHICAGO	IL	60654
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
<a href="#">GTCR PARTNERS XI/A&amp;C LP</a>		
(Last)	(First)	(Middle)
C/O GTCR LLC		
300 N. LASALLE SUITE 5600		
(Street)		
CHICAGO	IL	60654
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
<a href="#">GTCR PARTNERS XI/B LP</a>		
(Last)	(First)	(Middle)
C/O GTCR LLC		
300 N. LASALLE SUITE 5600		
(Street)		
CHICAGO	IL	60654
(City)	(State)	(Zip)

**Explanation of Responses:**

- On November 24, 2020, the Issuer used a portion of the net proceeds from the closing of its initial public offering ("IPO") of Class A common stock, par value \$0.01 per share (the "Class A Shares"), to repurchase 1,319,148 Class A Shares held by Maravai Life Sciences Holdings 2, LLC ("MLSH 2") and to purchase 55,823,011 common units (the "Common Units") of Maravai Topco Holdings, LLC ("Topco LLC") from Maravai Life Sciences Holdings, LLC ("MLSH 1"), who were the Issuer's pre-IPO equityholders, at a price of \$25.5150 per Class A Share or Common Unit.
- Reflects Class A Shares held directly by MLSH 2. MLSH 2 is managed by a board of managers controlled by GTCR Fund XI/C LP ("GTCR Fund XI/C"). GTCR Partners XI/A&C LP ("GTCR Partners XI/A&C") is the general partner of GTCR Fund XI/C. GTCR Investment XI LLC ("GTCR Investment XI") is the general partner of GTCR Partners XI/A&C. GTCR Investment XI is managed by a board of managers (the "GTCR Board of Managers") consisting of Mark M. Anderson, Craig A. Bondy, Aaron D. Cohen, Sean L. Cunningham, Benjamin J. Daverman, David A. Donnini, Constantine S. Mihos and Collin E. Roche, and no single person has voting or dispositive authority over the Class A Shares.
- (Continued From Footnote 2) Each of GTCR Partners XI/A&C, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the Class A Shares held of record by MLSH 2, and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the Class A Shares held of record by MLSH 2 except to the extent of his pecuniary interest therein.
- Reflects shares of the Issuer's Class B common stock, par value \$0.01 (the "Class B Shares") forfeited and canceled for no consideration by MLSH 1 in connection with the purchase by the Issuer of the Common Units.
- Reflects Class B Shares held directly by Maravai Life Sciences Holdings, LLC ("MLSH 1"). MLSH 1 is managed by a board of managers controlled by GTCR Fund XI/B LP ("GTCR Fund XI/B") and GTCR Co-Invest XI LP ("GTCR Co-Invest XI"). GTCR Partners XI/B LP ("GTCR Partners XI/B") is the general partner of GTCR Fund XI/B. GTCR Investment XI is the general partner of GTCR Co-Invest XI and GTCR Partners XI/B. GTCR Investment XI is managed by the GTCR Board of Managers, and no single person has voting or dispositive authority over the Class B Shares. Each of GTCR Partners XI/B, GTCR Investment XI and the GTCR Board of Managers may be deemed to share beneficial ownership of the Class B shares held of record by MLSH 1, and each of the individual members of the GTCR Board of Managers disclaims beneficial ownership of the Class B shares held of record by MLSH 1 except to the extent of his pecuniary interest therein.
- Pursuant to the Exchange Agreement dated November 19, 2020, by and among the Issuer, Topco LLC and MLSH 1 (the "Exchange Agreement"), the Common Units (together with one Class B Share for every Common Unit) are exchangeable for one Class A Share. Common Units do not expire.
- Reflects Common Units owned directly by MLSH 1. Each Common Unit is exchangeable for one Class A Share pursuant to the Exchange Agreement.

**Remarks:**

Each of the reporting persons is a director-by-deputization solely for purposes of Section 16 of the Securities Exchange Act of 1934.

/s/ Carl Hull, as chief executive 11/27/2020

<a href="#"><u>officer of Maravai Life Sciences Holdings, LLC</u></a>	
<a href="#"><u>/s/ Carl Hull, as chief executive officer of Maravai Life Sciences Holdings 2, LLC</u></a>	<a href="#"><u>11/27/2020</u></a>
<a href="#"><u>/s/ Jeffrey Wright, by power of attorney for GTCR Fund XI/B LP</u></a>	<a href="#"><u>11/27/2020</u></a>
<a href="#"><u>/s/ Jeffrey Wright, by power of attorney for GTCR Fund XI/C LP</u></a>	<a href="#"><u>11/27/2020</u></a>
<a href="#"><u>/s/ Jeffrey Wright, by power of attorney for GTCR Co-Invest XI LP</u></a>	<a href="#"><u>11/27/2020</u></a>
<a href="#"><u>/s/ Jeffrey Wright, by power of attorney for GTCR Partners XI/A&amp;C LP</u></a>	<a href="#"><u>11/27/2020</u></a>
<a href="#"><u>/s/ Jeffrey Wright, by power of attorney for GTCR Partners XI/B LP</u></a>	<a href="#"><u>11/27/2020</u></a>
<a href="#"><u>/s/ Jeffrey Wright, by power of attorney for GTCR Investment XI LLC</u></a>	<a href="#"><u>11/27/2020</u></a>

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**